HK1249036A1 - 用於治疗hiv相关性腹泻的方法和组合物 - Google Patents

用於治疗hiv相关性腹泻的方法和组合物 Download PDF

Info

Publication number
HK1249036A1
HK1249036A1 HK18108819.2A HK18108819A HK1249036A1 HK 1249036 A1 HK1249036 A1 HK 1249036A1 HK 18108819 A HK18108819 A HK 18108819A HK 1249036 A1 HK1249036 A1 HK 1249036A1
Authority
HK
Hong Kong
Prior art keywords
crofelemer
day
subject
hiv
administration
Prior art date
Application number
HK18108819.2A
Other languages
English (en)
Chinese (zh)
Inventor
Forbes William
Bortey Enoch
King Steven
Chaturvedi Pravin
Original Assignee
Napo Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1249036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals, Inc. filed Critical Napo Pharmaceuticals, Inc.
Publication of HK1249036A1 publication Critical patent/HK1249036A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK18108819.2A 2010-10-31 2018-07-09 用於治疗hiv相关性腹泻的方法和组合物 HK1249036A1 (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US61/408622 2010-10-31
US40933510P 2010-11-02 2010-11-02
US61/409335 2010-11-02
US41624910P 2010-11-22 2010-11-22
US61/416249 2010-11-22
US201161434379P 2011-01-19 2011-01-19
US61/434379 2011-01-19

Publications (1)

Publication Number Publication Date
HK1249036A1 true HK1249036A1 (zh) 2018-10-26

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108819.2A HK1249036A1 (zh) 2010-10-31 2018-07-09 用於治疗hiv相关性腹泻的方法和组合物

Country Status (20)

Country Link
US (4) US8962680B2 (cg-RX-API-DMAC10.html)
EP (1) EP2632550B1 (cg-RX-API-DMAC10.html)
JP (2) JP6063385B2 (cg-RX-API-DMAC10.html)
CN (2) CN103370101A (cg-RX-API-DMAC10.html)
AU (1) AU2011320155B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013010774A2 (cg-RX-API-DMAC10.html)
CA (1) CA2816416C (cg-RX-API-DMAC10.html)
DK (1) DK2632550T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP13012650A (cg-RX-API-DMAC10.html)
ES (1) ES2635435T3 (cg-RX-API-DMAC10.html)
HK (1) HK1249036A1 (cg-RX-API-DMAC10.html)
HU (1) HUE035393T2 (cg-RX-API-DMAC10.html)
MX (1) MX348184B (cg-RX-API-DMAC10.html)
PE (1) PE20140036A1 (cg-RX-API-DMAC10.html)
PH (1) PH12013500857A1 (cg-RX-API-DMAC10.html)
PL (1) PL2632550T3 (cg-RX-API-DMAC10.html)
PT (1) PT2632550T (cg-RX-API-DMAC10.html)
RU (1) RU2597746C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012058664A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201303136B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
PT2529626T (pt) 2006-05-01 2018-02-27 Napo Pharmaceuticals Inc Composições e métodos para tratamento ou prevenção do cancro do cólon
NZ572049A (en) 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
WO2012058664A1 (en) 2010-10-31 2012-05-03 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
JP2016505561A (ja) * 2012-12-07 2016-02-25 サリックス ファーマスーティカルズ,リミテッド Hiv関連下痢を治療する方法および組成物
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
AU2018275685B2 (en) 2017-05-31 2025-04-17 Napo Pharmaceuticals, Inc. Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
JP2020525407A (ja) 2017-05-31 2020-08-27 ナポ ファーマシューティカルズ インク.Napo Pharmaceuticals,Inc. 先天性下痢障害を治療するための方法及び組成物
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ, インコーポレイテッド 機械学習を使用するデータ圧縮および通信
MX2022016367A (es) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ,インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
WO2005074575A2 (en) * 2004-01-30 2005-08-18 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1937655A1 (en) * 2005-06-22 2008-07-02 University of Massachusetts Hiv-1 protease inhibitors, and methods of making and using them
CA2633417A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
NZ572049A (en) * 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
PT2529626T (pt) 2006-05-01 2018-02-27 Napo Pharmaceuticals Inc Composições e métodos para tratamento ou prevenção do cancro do cólon
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011024049A2 (en) 2009-08-26 2011-03-03 Glenmark Pharmaceuticals Ltd Method for producing proanthocyanidin polymer compositions for pharmaceutical formulations
AU2010303577B2 (en) * 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
WO2012058664A1 (en) 2010-10-31 2012-05-03 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
WO2012101008A1 (en) 2011-01-27 2012-08-02 Glenmark Pharmaceuticals Limited Process for the production of proanthocyanidin polymeric composition
MX2014007635A (es) 2011-12-22 2014-09-22 Glenmark Pharmaceuticals Ltd Composicion farmaceutica no enterica que comprende crofelemer.
JP2016505561A (ja) 2012-12-07 2016-02-25 サリックス ファーマスーティカルズ,リミテッド Hiv関連下痢を治療する方法および組成物

Also Published As

Publication number Publication date
ZA201303136B (en) 2016-01-27
CN103370101A (zh) 2013-10-23
JP6063385B2 (ja) 2017-01-18
ES2635435T3 (es) 2017-10-03
PL2632550T3 (pl) 2017-10-31
EP2632550A4 (en) 2014-04-23
EP2632550A1 (en) 2013-09-04
AU2011320155A1 (en) 2013-05-09
US9585868B2 (en) 2017-03-07
US8962680B2 (en) 2015-02-24
MX348184B (es) 2017-06-02
ECSP13012650A (es) 2013-10-31
US20120107370A1 (en) 2012-05-03
PH12013500857A1 (en) 2018-01-17
BR112013010774A2 (pt) 2017-03-21
EP2632550B1 (en) 2017-05-03
US20120184605A1 (en) 2012-07-19
WO2012058664A1 (en) 2012-05-03
CA2816416C (en) 2020-02-11
PE20140036A1 (es) 2014-01-31
AU2011320155B2 (en) 2016-02-25
CN107595836A (zh) 2018-01-19
US20150190367A1 (en) 2015-07-09
RU2597746C2 (ru) 2016-09-20
JP6310971B2 (ja) 2018-04-11
RU2013123794A (ru) 2014-12-10
JP2017019806A (ja) 2017-01-26
HUE035393T2 (en) 2018-05-02
US20140294903A1 (en) 2014-10-02
CA2816416A1 (en) 2012-05-03
DK2632550T3 (en) 2017-08-07
PT2632550T (pt) 2017-08-02
JP2013540826A (ja) 2013-11-07
MX2013004873A (es) 2013-08-21

Similar Documents

Publication Publication Date Title
CA2816416C (en) Methods and compositions for treating hiv-associated diarrhea
JP2016505561A (ja) Hiv関連下痢を治療する方法および組成物
US20240325346A1 (en) Methods and compositions for treating congenital diarrhea disorder
EP3634455B1 (en) Compositions for treating bile acid diarrhea and short bowel syndrome
WO2022115481A1 (en) Methods and compositions for treating post-acute infection gastrointestinal disorders
HK1183263B (en) Methods and compositions for treating hiv-associated diarrhea
HK1183263A (en) Methods and compositions for treating hiv-associated diarrhea
HK40016516A (en) Compositions for use in treating congenital diarrhea disorder
HK40016517B (en) Compositions for treating bile acid diarrhea and short bowel syndrome
HK40016517A (en) Compositions for treating bile acid diarrhea and short bowel syndrome
HK40015132A (en) Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome